About Reata Pharma
Reata Pharma is a Healthcare company based in Irving (United States) founded in 2002, and was acquired by Biogen in July 2023. Small molecules for melanoma, pulmonary hypertension, friedreichs ataxia, mitochondrial myopathies and cataract surgery patients. Reata Pharma has raised $428.95 million across 7 funding rounds from investors including SVB, Blackstone and Biogen. The company has 363 employees. Its chief executive, as recorded, is Warren Huff. Reata Pharma offers products and services including Alzheimer's Therapy, Multiple Sclerosis Drug, Amyotrophic Lateral Sclerosis Treatment, and Spinal Muscular Atrophy Medicine. Its focus areas include Diversified Pharmaceuticals.
Company details
Reata Pharma was founded in 2002 and is headquartered in Irving, United States. Operations focus on the pharmaceutical sector, where small molecules are developed to address melanoma, pulmonary hypertension, Friedreichs ataxia, mitochondrial myopathies, and needs of cataract surgery patients. Research and development efforts target these specific therapeutic areas to support clinical applications.
- Headquarters Irving, United States
- Employees 363
- Stage Acquired
- SectorsHealthcare
- Website reatapharma.com
- Social LinkedIn X
- Acquired by Biogen (Jul 2023)
- Annual Revenue$2.22 M (USD)-81as on Dec 31, 2022
- Net Profit-$311.9 M (USD)-5as on Dec 31, 2022
- EBITDA-$344.69 M (USD)1as on Dec 31, 2022
- Total Equity Funding$428.95M (USD)
in 7 rounds
- Latest Funding Round$50M (USD), Post-IPO
Jun 2020
- InvestorsSVB
& 4 more
- Employee Count363
- Acquired byBiogen
(Jul 2023)
Products & Services of Reata Pharma
Reata Pharma offers a comprehensive portfolio of products and services, including Alzheimer's Therapy, Multiple Sclerosis Drug, Amyotrophic Lateral Sclerosis Treatment, and Spinal Muscular Atrophy Medicine.
Treatment for Alzheimer's disease symptoms
Medication for managing multiple sclerosis progression
Therapy for amyotrophic lateral sclerosis patients
Support for spinal muscular atrophy conditions
Funding Insights of Reata Pharma
Reata Pharma has successfully raised a total of $428.95M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $428.95M
- Total Rounds 7
- Last Round Post-IPO — $50M
- First Round $32M
(Mar 2009)
- Investors Count 4
All 7 funding rounds of Reata Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $50M | Post-IPO | – | – | |
| Jun 2018 | $80M | Debt – Venture | – | – | |
| Jul 2011 | $300M | Series E | – | – | – |
| Jul 2010 | $78M | Series D | – | Novo Holdings | – |
| Feb 2010 | $1.97M | Series C | – | – | – |
| Sep 2009 | $16.98M | Series C | – | – | – |
| Mar 2009 | $32M | Series C | – | – | – |
5 investors in total: 5 institutional.
Investors in Reata Pharma
Reata Pharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Blackstone and Biogen.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Therapies for neurodegenerative and immunology disorders are developed. | 1978 | biogen.com | Cambridge, United States |
Investor details for Reata Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Reata Pharma
898 people are tracked at Reata Pharma (447 in leadership, 10 in board & advisors, 441 in team); the tracked headcount is 363.
| Name | Role | Group |
|---|---|---|
Warren Huff | CEO | Leadership |
Michael Schindelar | Sr. Director Development Asset Lead | Leadership |
Andrei Huang | Head Of HPC | Leadership |
Jane Grogan | Head, Research | Leadership |
Katherine Dawson | Senior Vice President, Therapeutics Development Unit; Director, Biogen Foundation | Leadership |
Maria F. | Head Of People Relations And Governance | Leadership |
Holly M. Brothers | Associate Medical Director | Leadership |
Jerome Hanna | Executive Medical Director, Multiple Sclerosis Clinical Development | Leadership |
Rosalind McCully | Associate Director, CMC Global Regulatory Lead | Leadership |
Devendra Singh | Associate Director - Ma&r Insights & Patient Access | Leadership |
Emanuel de Duonni | Global Asset Head | Skyclarys & Friedreich’s Ataxia | Executive Director | Leadership |
Chris Helal | Head Of Synthetic Medicine Design | Leadership |
Samir Koirala | Head Of Genetic, Neurodevelopmental & Epilepsy Disorders Research | Leadership |
Karuna Beecharaju | Associate Director, Commercial Information Management | Leadership |
Masami Hayami | Japan HR Head | Leadership |
Alejandro Parra | Marketing Operations Lead - INT Partner Markets | Leadership |
Brian Hopkins | Director, CMC At Biogen | Leadership |
Gioacchino C. | Senior Medical Director | Leadership |
Jim Dorsey | Director, Clinical Data Management | Leadership |
Monique Bueno Alves | Head Of Medical For Australia & New Zealand | Leadership |
878 more people are available in the full profile.
Complete people profiles for Reata Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Reata Pharma
5 dated milestones of Reata Pharma across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Reata Pharma is founded.
- Funding First funding round of $32.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
- Exit Acquired by Biogen.
Web traffic of Reata Pharma
Websites that share an audience with Reata Pharma (reatapharma.com).
Websites whose visitors overlap most with Reata Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| phadia.com | 100% | 5.1K | #3,952,566 | View details | |
| lundbeck.com | 100% | 137.6K | #280,857 | View details | |
| cambrex.com | 100% | 35K | #883,665 | View details | |
| optimerpharma.com | 100% | View details | |||
| halozyme.com | 100% | 11.6K | #1,481,510 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Reata Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
3 companies that operate in the same segment as Reata Pharma (Pharmaceuticals & Distribution) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | USD 33.23 B | 28,000 | ||
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | USD 5.33 B | 55,000 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Reata Pharma
Complete news archive for Reata Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Reata Pharma
Reata Pharma was founded in 2002 and raised its 1st funding round 7 years after it was founded.
Reata Pharma is headquartered in Irving, United States. It is registered at Irving, Texas, United States.
Warren Huff is the CEO of Reata Pharma, as recorded in our data.
Reata Pharma is a funded company, having raised a total of $428.95M across 7 funding rounds to date. The company's 1st funding round was a Series C of $32M, raised on Mar 2009.
Reata Pharma has 363 employees.
Annual revenue of Reata Pharma is $2.22M as on Dec 31, 2022.
Reata Pharma was founded in 2002 and is headquartered in Irving, United States. Operations focus on the pharmaceutical sector, where small molecules are developed to address melanoma, pulmonary hypertension, Friedreichs ataxia, mitochondrial myopathies, and needs of cataract surgery patients. Research and development efforts target these specific therapeutic areas to support clinical applications.
Reata Pharma offers Alzheimer's Therapy, Multiple Sclerosis Drug, Amyotrophic Lateral Sclerosis Treatment, and Spinal Muscular Atrophy Medicine.
Reata Pharma has 5 investors. Key investors include SVB, Blackstone, Biogen, Oxford Finance, and Novo Holdings.
Yes. Reata Pharma was acquired by Biogen in July 2023.